The global Lassa fever treatment market is estimated to grow at a significant CAGR over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the increasing incidences of Lassa fever, especially in the Middle East and Africa region, backed by lack of sanitation and proper healthcare facilities in the region. The major cause of Lassa fever is consumption of food or water contaminated with rodent urine or faeces. According to the data by the UNICEF, 5 out of 10 people do not have access to safe sanitation services, in 2020. Moreover, growing cases of the fever across the world, is projected to promote the market growth. According to the data by the World Health Organization (WHO), 1 in every 5 Lassa fever infections result in severe infection in organs. Moreover, in 80% cases, no symptoms are reported. Symptoms can vary from mild symptoms, such as, nausea, and vomiting, to severe symptoms, such as, deafness, seizure, and coma. As per another report by the WHO, deafness occurs in 25% of the cases of Lassa fever.
The market is segmented by treatment into medication, supportive care, and others, out of which, the medication segment is anticipated to hold the largest share in the global Lassa fever treatment market over the forecast period on account of fast relief action of the drugs, quicker symptom elevation, and easy availability in pharmacies.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years. CLICK TO DOWNLOAD SAMPLE REPORT
On the basis of geographical analysis, the global Lassa fever treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Middle East and Africa region is estimated to witness noteworthy growth over the forecast period on the back of increasing incidences of Lassa fever in the region. Lack of proper sanitation services in the region is also expected to significantly fuel the regional market growth. According to the statistics by the WHO, around 2 billion people do not have basic sanitation facilities, such as, toilets, especially in middle and low-income economies. Improving healthcare facilities, backed by increasing investment in the sector is further estimated to boost the market growth. According to the data by the World Bank, USD 520.89 were spent per capita on healthcare in the Middle East and North Africa region, in 2018.
The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the presence of major pharmaceutical companies in the region, along with high investment for research and development of new drugs.
The global Lassa fever treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the global Lassa fever treatment market includes the following segments:
FREQUENTLY ASKED QUESTIONS
Increasing investment to improve healthcare sector in underdeveloped economies is estimated to boost the market growth.
The market is anticipated to attain a significant CAGR over the forecast period, i.e., 2022 – 2030.
Lack of health awareness amongst people in the low-income countries is estimated to hamper the market growth.
The market in the North America region is estimated to provide more business opportunities owing to the presence of major pharmaceutical companies in the region.
The major players in the market are Mylan N.V., Novartis International AG, Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by symptoms, treatment, and by region.
The medications segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization